

## **KISUNLA® ORDER FORM**

FAX TO: 855.694.4656

## PATIENT INFORMATION

| PATIENT NAME:   |  | PHONE:  |  |
|---|--|---|--|
| DATE OF BIRTH: SI   | EX: M F HEIGHT:  | WEIGHT:   | LBS KG   |
| ALLERGIES:  | PREFERRED CLINIC:  |   |  |
| REFERRAL STATUS: NEW REFERE   | RAL ORDER CHANGE   | ORDER RENEWAL   |  |
| DIAGNOSIS & CLINICAL D  | OCUMENTATION   |   |  |
| G30.0 Alzheimer's disease with each G30.1 Alzheimer's disease with la G30.8 Other Alzheimer's disease ICD-10 CODE: DESC   | te onset G31.84  | Alzheimer's disease, uns<br>Mild cognitive impairmer  | nt, so stated  |
|   | REQUIRED DOCUMENT  | TATION  |  |
|   | Most Recent History & Physical  Ifirmed Amyloid Recent History & Recent Hi | Tried & Failed Therapies t MRI prior to initiating  | Cognitive Assessment & Score  Proof of CED registry submission |
| MEDICATION ORDER  |  | PRE-MED   | ICATIONS   |
| *Referring provider responsible for obtaining MRI prior to infusion #2, #4 and #7 for monitoring of ARIA  LOADING: Kisunla® (donanemab) 700mg IV in 100ml NS over 30 minutes at week 0, week 4 and week 8 |  | PO Acetaminophen: 650 mg Cetirizine: 10 mg Diphenhydramine: 25 mg  IV Methylprednisolone: 125 mg Diphenhydramine: 25 mg PO IV |  |
| <ul> <li>MAINTENANCE: Kisunla® (donanemab) 1400mg IV in 250ml NS over 30 minutes every 4 weeks</li> <li>*Maintenance dosing scheduled 4 weeks from last loading dose 8 dose)</li> </ul>                   |  |   |  |
| ▼ REFILL X 12 MONTHS UNLESS OTHE  | RWISE NOTED HERE:  | I   |  |
| Patient to be observed for 30 minutes following each administration in the event of an adverse reaction occurring in the infusion clinic, ut  PRESCRIBER INFORMATI  PROVIDER NAME:                        | ilize the Immersiv Health adverse reaction protocol.   | NPI#:   |  |
| EMAIL:  |  |   |  |
| ADDRESS (INCLUDE CITY, STATE, ZIP SUPERVISING PHYSICIAN:  | ):   |   |  |
| SIGNATURE: (NO STAMPS) SUBSTITUTION PERMIT  | DATE:  DISPENSE AS WRITTEN   |   |  |